Questions? Feedback? powered by Olark live chat software
All Site

Get superior yields of rAAV virus production in suspension cells

A major challenge today is manufacturing sufficient quantities of AAV in order to treat larger groups of patients. Polyplus FectoVIR®-AAV is a novel class of animal free transfection reagent specifically developed for industrial scale production of recombinant AAV (rAAV) viral vectors in suspension HEK-293 cell types.

Polyplus FectoVIR®-AAV transfection reagent guarantees higher rAAV viral titers, improved flexibility and scalability for industrial scale manufacturing.

FectoVIR®-AAV outperforms its main competitors for AAV production in suspension cells



FectoVIR®-AAV allows a flexible process for small to large scale suspension cell systems

Optimized to reduce complexation volumes down to 1% enabling larger transfection volumes

Longer stability of transfection complexes, providing longer timeframe to handle larger volumes

Frequently asked questions about FectoVIR®-AAV

The FectoVIR®-AAV structure is confidential and a patent has been filed. PEIpro® and FectoVIR® AAV are different both in terms of molecular structure and formulation.

Please contact our scientific support using our Contact us form and we will provide protocol with starting conditions as well as a range for optimizations needed to get optimal results.

Polyplus has successfully used FectoVIR®-AAV on suspension HEK 293 derivatives (293T, 293F) and high density derivatives (Expi29 3™ cells). Beta testers confirmed that FectoVIR®- AAV works well in several commercial and proprietary suspension HEK 293 subclones.

In house, Polyplus produce both AAV-2 and AAV-5. More serotypes have been tested by their beta testers, with comparable yield improvements.

FectoVIR®-AAV shows a remarkable improvement in terms of viral titers in suspension system and is less efficient in adherent systems for which PEIpro® remains the transfection reagent of choice.

For lentivirus production, we recommend PEIpro® the gold standard for virus production as it is currently the best product for this application, both in adherent and suspension cell culture systems.

Looking for an automated platform for consistent expansion?

Meet Quantum

The Quantum system is an automated cell culture platform that can help simplify the open, labor-intensive manual tasks associated with flask-based culture. Manufacturing is a strategic asset in cell therapy. Planning to scale a flaskbased process can be complicated and time-consuming; it requires a significant investment in labor and resources and may introduce complexity and variability to your manufacturing process. The early adoption of an automated cell culture platform can help streamline your process and reduce the obstacles to manufacturing scale-up or scale-out.

  • Expansion of adherent and suspension cells, as well as plasmid transfections and viral transductions
  • Cell doubling times and cell quality comparable to manual flask-based culture
  • Production of cells with consistent yields and cell quality
  • Maintaining cell characteristics consistent with flasks
  • Stable cell culture environment for both hypoxic and normoxic conditions
  • Software features aid in Part 11 current Good Manufacturing Practices (cGMP) compliance.


Discover what Quantum can do for you
Lower Risk of Contamination

Enable Reproducible, Scalable Processes
Control Process
Reduced Variability
Exercise Flexibility

Protocol Flexibility

Featured Articles

  • Peer-Reviewed Article: Comparison of Automated Perfusion - and Manual Diffusion-Based Human Regulatory T-Cell Expansion and Functionality Using a Soluble Activator Complex

Click here to view

  • Peer-Reviewed Article: Large-Scale Expansion and Characterization of CD3+ T Cells in the Quantum Cell Expansion System

Click here to view

Home Banner CGT